Novalis Biotech is an early-stage venture capital fund in life sciences.
Novalis was founded by Prof. Wim Van Criekinge and Jan Van den Berghe.
As an early-stage private equity/venture capital fund, we are a dynamic and flexible player not restricting ourselves to specific fields of expertise, but open to discussing any proposition in the field of life sciences.
They differentiate ourselves by high dynamism and flexibility to rapidly evolve our portfolio companies.
Their investment ideas focus on the interaction between bioinformatics and life sciences. They strongly believe in applying innovative information technology to advance the prevention, diagnosis, or treatment of diseases. Novalis focuses on capital-light business models and platform technology.
Their investment focus is “enabling technologies” in life sciences. They strongly believe in capital light platform technology and close interaction with customers already early in the life of the company. Focus areas are: innovative research and manufacturing tools, bioinformatics, genomics, diagnostics and digital health. They focus on early-stage start-ups, from (pre-)seed stage to series A, and support their evolution by providing funding, sharing Their professional and academic connections, and help to shape the business strategy in order to create value for all stakeholders.
office: Novalis Biotech MeetDistrict – 5th floor Ottergemsesteenweg – Zuid 808 9000 Gent Belgium The fund’s official address Novalis II Comm V Ottergemsesteenweg Zuid 808 B511 9000 Ghent Belgium Company number: 0757.877.529
